newsfilter
← Latest News
GlobeNewswire·

Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient administration and